Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.

Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, Lee B, Cho JH, Faragher I, Jones IT, Ptak J, Schaeffer MJ, Silliman N, Dobbyn L, Li L, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P.

Open source

DOI: 10.1001/jamaoncol.2019.3616
Published: 2019-12-01
Container: JAMA Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2019.3616,
  title = {Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.},
  author = {Tie J and  Cohen JD and  Wang Y and  Christie M and  Simons K and  Lee M and  Wong R and  Kosmider S and  Ananda S and  McKendrick J and  Lee B and  Cho JH and  Faragher I and  Jones IT and  Ptak J and  Schaeffer MJ and  Silliman N and  Dobbyn L and  Li L and  Tomasetti C and  Papadopoulos N and  Kinzler KW and  Vogelstein B and  Gibbs P.},
  year = {2019},
  journal = {JAMA Oncol},
  doi = {10.1001/jamaoncol.2019.3616},
  url = {https://doi.org/10.1001/jamaoncol.2019.3616}
}

RIS

TY  - JOUR
TI  - Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
AU  - Tie J
AU  -  Cohen JD
AU  -  Wang Y
AU  -  Christie M
AU  -  Simons K
AU  -  Lee M
AU  -  Wong R
AU  -  Kosmider S
AU  -  Ananda S
AU  -  McKendrick J
AU  -  Lee B
AU  -  Cho JH
AU  -  Faragher I
AU  -  Jones IT
AU  -  Ptak J
AU  -  Schaeffer MJ
AU  -  Silliman N
AU  -  Dobbyn L
AU  -  Li L
AU  -  Tomasetti C
AU  -  Papadopoulos N
AU  -  Kinzler KW
AU  -  Vogelstein B
AU  -  Gibbs P.
PY  - 2019
JO  - JAMA Oncol
DO  - 10.1001/jamaoncol.2019.3616
UR  - https://doi.org/10.1001/jamaoncol.2019.3616
ER  -

APA

J, T., JD, C., Y, W., M, C., K, S., M, L., R, W., S, K., S, A., J, M., B, L., JH, C., I, F., IT, J., J, P., MJ, S., N, S., L, D., L, L., C, T., N, P., KW, K., B, V., & P., G. (2019). Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.3616

Source records

europe-pmc · retrieved 2026-09-26T12:53:43.479Z